Primaa
Primaa develops AI-based software for histological diagnoses, improving a vital step in the detection of cancer.
Primaa develops AI-based software for histological diagnoses, improving a vital step in the detection of cancer.
Primaa is a France-based startup founded in 2018 that specializes in the development of AI-based software for histological diagnoses. The company's slogan succinctly captures the essence of their mission, which is to improve the detection of cancer through innovative AI technology. Primaa's focus on the Health Care industry aligns with the growing trend of utilizing artificial intelligence to enhance healthcare outcomes.
The company recently secured a significant milestone with a €2.00M Seed Round investment on 11 October 2019. The investors involved in this round, including 50 Partners, Angels Santé, Pleiade Venture, Damien Guermonprez, Fonds Ambition Amorçage Angels, and Entrepreneurs Investis, represent a diverse group committed to supporting Primaa's innovative approach to cancer diagnosis and treatment.
Primaa's commitment to leveraging AI for histological and cancer diagnoses positions the company at the forefront of a transformative trend in healthcare. The recent investment signifies a vote of confidence from prominent investors and highlights the potential for Primaa to make significant strides in advancing cancer detection and patient care.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | €2.00M | 6 |
|
11 Oct 2019 |
| Non Equity Assistance | Unknown | 1 |
|
01 Jul 2018 |
No recent news or press coverage available for Primaa.
We care about your data, and we'd love to use cookies make your experience better.
